-
公开(公告)号：US08753633B2
公开(公告)日：2014-06-17
申请号：US13524525
申请日：2012-06-15
Applicant: Jochen G. Salfeld , Deborah J. Allen , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , Hendricus R. J. M. Hoogenboom , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
Inventor： Jochen G. Salfeld , Deborah J. Allen , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , Hendricus R. J. M. Hoogenboom , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
IPC: C07K16/24 , A61K38/00 , A61K39/395
CPC classification number: C07K16/241 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , Y02A50/412 , Y10S424/81
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Abstract translation: 公开了特异性结合人肿瘤坏死因子α（hTNFα）的人抗体，优选重组人抗体。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 本发明的抗体或抗体部分可用于检测hTNFα和抑制hTNFα活性，例如在患有hTNFα活性有害的病症的人类受试者中。 用于表达本发明的重组人抗体的核酸，载体和宿主细胞以及合成重组人抗体的方法也包括在本发明中。
-
32.发明申请AQUEOUS-BASED PERSONAL CARE PRODUCT FORMULA THAT COMBINES FRICTION-CONTROLLED FRAGRANCE ENCAPSULATION TECHNOLOGY WITH A FILM FORMING COMPOUND 审中-公开基于水性的个人护理产品配方与电影形成化合物组合摩擦控制的香料包封技术公开(公告)号：US20130171216A1
公开(公告)日：2013-07-04
申请号：US13341048
申请日：2011-12-30
Applicant: Ethan Alden-Danforth , William Feuer , Michael White , Nancy Williams
Inventor： Ethan Alden-Danforth , William Feuer , Michael White , Nancy Williams
CPC classification number: A61K8/11 , A61K8/342 , A61K8/604 , A61K2800/412 , A61Q15/00
Abstract: The present disclosure relates to an aqueous microcapsule composition comprising a plurality of microcapsule particles, a film-forming mixture, and an aqueous solvent. Each microcapsule particle comprises a sol-gel material and a volatile oil-soluble active ingredient encapsulated by the sol-gel material. The film-forming mixture of the present disclosure extends the efficacy of the volatile oil-soluble active ingredient encapsulated in the microcapsule particles by improving the adherence of the microcapsule particles to the substance to which the aqueous microcapsule composition is applied (e.g., a keratinous substance or a fabric). The aqueous microcapsule composition of the instant disclosure—which is free of formaldehyde and stable in aqueous solvents—is well-suited for use in aqueous personal care products.
Abstract translation: 本公开内容涉及包含多个微胶囊颗粒，成膜混合物和水性溶剂的水性微胶囊组合物。 每个微胶囊颗粒包含溶胶 - 凝胶材料和由溶胶 - 凝胶材料包封的挥发性油溶性活性成分。 本公开的成膜混合物通过改善微胶囊颗粒对应用水性微胶囊组合物的物质（例如，角质物质）的粘附来延长包封在微胶囊颗粒中的挥发性油溶性活性成分的功效 或织物）。 本公开的水性微胶囊组合物 - 其不含甲醛并且在水性溶剂中稳定 - 非常适合用于水性个人护理产品。
-
33.发明授权公开(公告)号：US08372400B2
公开(公告)日：2013-02-12
申请号：US12578487
申请日：2009-10-13
Applicant: Jochen G. Salfeld , Deborah J. Allen , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , Hendricus R. J. M. Hoogenboom , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
Inventor： Jochen G. Salfeld , Deborah J. Allen , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , Hendricus R. J. M. Hoogenboom , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
IPC: A61K39/395
CPC classification number: C07K16/241 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , Y02A50/412 , Y10S424/81
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Abstract translation: 公开了特异性结合人肿瘤坏死因子α（hTNFα）的人抗体，优选重组人抗体。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 本发明的抗体或抗体部分可用于检测hTNFα和抑制hTNFα活性，例如在患有hTNFα活性有害的病症的人类受试者中。 用于表达本发明的重组人抗体的核酸，载体和宿主细胞以及合成重组人抗体的方法也包括在本发明中。
-
公开(公告)号：US20120308514A1
公开(公告)日：2012-12-06
申请号：US13429104
申请日：2012-03-23
Applicant: Jochen Salfeld , Michael Roguska , Michael Paskind , Subhashis Banerjee , Daniel Tracey , Michael White , Zehra Kaymakcalan , Boris Labkovsky , Paul Sakorafas , Geertruida M. Veldman , Amy Venturini , Angela Widom , Stuart Friedrich , Nicholas W. Warne , Angela Myles , John Gawain Elvin , Alexander Robert Duncan , Elaine Joy Derbyshire , Sara Carmen , Stephen Smith , Thor Las Holtet , Sarah Leila Du Fou
Inventor： Jochen Salfeld , Michael Roguska , Michael Paskind , Subhashis Banerjee , Daniel Tracey , Michael White , Zehra Kaymakcalan , Boris Labkovsky , Paul Sakorafas , Geertruida M. Veldman , Amy Venturini , Angela Widom , Stuart Friedrich , Nicholas W. Warne , Angela Myles , John Gawain Elvin , Alexander Robert Duncan , Elaine Joy Derbyshire , Sara Carmen , Stephen Smith , Thor Las Holtet , Sarah Leila Du Fou
IPC: A61K39/395 , A61K38/19 , A61P19/02 , A61P1/00 , A61P1/04 , A61P9/10 , A61P11/06 , A61P13/12 , A61P1/16 , A61P25/28 , A61P25/16 , A61K38/20 , A61P3/10
CPC classification number: C07K16/244 , A61K9/0019 , A61K38/208 , A61K39/00 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K47/20 , A61K47/22 , A61K47/26 , A61K2039/505 , C07K14/5434 , C07K16/00 , C07K16/18 , C07K2317/21 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/94 , Y10S514/863 , Y10S514/885 , Y10S514/886
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
35.发明授权Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa 有权使用结合人TNFα的人抗体治疗类风湿性关节炎的方法公开(公告)号：US08206714B2
公开(公告)日：2012-06-26
申请号：US12369451
申请日：2009-02-11
Applicant: Jochen G. Salfeld , Deborah J. Allen , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , Hendricus R. J. M. Hoogenboom , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
Inventor： Jochen G. Salfeld , Deborah J. Allen , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , Hendricus R. J. M. Hoogenboom , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
IPC: A61K39/395
CPC classification number: C07K16/241 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , Y02A50/412 , Y10S424/81
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Abstract translation: 公开了特异性结合人肿瘤坏死因子α（hTNFα）的人抗体，优选重组人抗体。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 本发明的抗体或抗体部分可用于检测hTNFα和抑制hTNFα活性，例如在患有hTNFα活性有害的病症的人类受试者中。 用于表达本发明的重组人抗体的核酸，载体和宿主细胞以及合成重组人抗体的方法也包括在本发明中。
-
Patent Agency Ranking
公开(公告)号：US20110184232A1
公开(公告)日：2011-07-28
申请号：US13057105
申请日：2009-07-31
Applicant: Vhairi Maxwell , Michael White , Michael McMahon
Inventor： Vhairi Maxwell , Michael White , Michael McMahon
CPC classification number: A61B17/00234 , A61B1/0051 , A61B2017/003 , A61B2017/320044 , A61M25/0068 , A61M25/0074 , A61M25/0138
Abstract: A series of integrally formed segments (24) are allowed to move relative to each other by flexure of hinges (26) that are also integrally formed with the sections.
Abstract translation: 一系列整体形成的段（24）允许通过也与这些部分一体形成的铰链（26）的弯曲而相对于彼此移动。
-
37.发明授权公开(公告)号：US07767207B2
公开(公告)日：2010-08-03
申请号：US09780035
申请日：2001-02-09
Applicant: Tariq Ghayer , Richard W. Dixon , Michael Roguska , Michael White , Boris Labkovsky , Jochen Salfeld , Alexander Robert Duncan , Simon Mark Brocklehurst , John Mankovich , Celia Patricia Shorrock , Julia Elizabeth Thompson , Simon Nicholas Lennard
Inventor： Tariq Ghayer , Richard W. Dixon , Michael Roguska , Michael White , Boris Labkovsky , Jochen Salfeld , Alexander Robert Duncan , Simon Mark Brocklehurst , John Mankovich , Celia Patricia Shorrock , Julia Elizabeth Thompson , Simon Nicholas Lennard
IPC: A61K39/395 , C07K16/24
CPC classification number: C07K16/244 , A61K31/519 , A61K31/56 , A61K38/13 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , A61K39/395 , A61K31/00
Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
Abstract translation: 提供了结合人白细胞介素-18（hIL-18）的抗体，特别是结合人IL-18表位的抗体。 抗体可以是例如完全是人抗体，重组抗体或单克隆抗体。 优选的抗体对hIL-18具有高亲和力，并在体外和体内中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性，例如在患有hIL-18活性有害的病症的人类受试者中。
-
38.发明申请公开(公告)号：US20100104563A1
公开(公告)日：2010-04-29
申请号：US09780035
申请日：2001-02-09
Applicant: Tariq Ghayer , Richard W. Dixon , Michael Roguska , Michael White , Boris Labkovsky , Jochen Salfeld , Alexander Robert Duncan , Simon Mark Brocklehurst , John Mankovich , Celia Patricia Shorrock , Julia Elizabeth Thompson , Simon Nicholas Lennard
Inventor： Tariq Ghayer , Richard W. Dixon , Michael Roguska , Michael White , Boris Labkovsky , Jochen Salfeld , Alexander Robert Duncan , Simon Mark Brocklehurst , John Mankovich , Celia Patricia Shorrock , Julia Elizabeth Thompson , Simon Nicholas Lennard
CPC classification number: C07K16/244 , A61K31/519 , A61K31/56 , A61K38/13 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , A61K39/395 , A61K31/00
Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
Abstract translation: 提供了结合人白细胞介素-18（hIL-18）的抗体，特别是结合人IL-18表位的抗体。 抗体可以是例如完全是人抗体，重组抗体或单克隆抗体。 优选的抗体对hIL-18具有高亲和力，并在体外和体内中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性，例如在患有hIL-18活性有害的病症的人类受试者中。
-
公开(公告)号：US20100040604A1
公开(公告)日：2010-02-18
申请号：US12578487
申请日：2009-10-13
Applicant: Jochen G. SALFELD , Deborah J. Allen , Hendricus R.J.M. Hoogenboom , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
Inventor： Jochen G. SALFELD , Deborah J. Allen , Hendricus R.J.M. Hoogenboom , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
IPC: A61K39/395
CPC classification number: C07K16/241 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , Y02A50/412 , Y10S424/81
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Abstract translation: 公开了特异性结合人肿瘤坏死因子α（hTNFα）的人抗体，优选重组人抗体。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 本发明的抗体或抗体部分可用于检测hTNFα和抑制hTNFα活性，例如在患有hTNFα活性有害的病症的人类受试者中。 用于表达本发明的重组人抗体的核酸，载体和宿主细胞以及合成重组人抗体的方法也包括在本发明中。
-
公开(公告)号：US20100016557A1
公开(公告)日：2010-01-21
申请号：US12401469
申请日：2009-03-10
Applicant: Jochen G. Salfeld , Deborah J. Allen , Hendricus R.J.M. Hoogenboom , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
Inventor： Jochen G. Salfeld , Deborah J. Allen , Hendricus R.J.M. Hoogenboom , Zehra Kaymakcalan , Boris Labkovsky , John A. Mankovich , Brian T. McGuinness , Andrew J. Roberts , Paul Sakorafas , David Schoenhaut , Tristan J. Vaughan , Michael White , Alison J. Wilton
CPC classification number: C07K16/241 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/92 , Y02A50/412 , Y10S424/80 , Y10S424/81 , Y10S530/868
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Abstract translation: 公开了特异性结合人肿瘤坏死因子α（hTNFα）的人抗体，优选重组人抗体。 这些抗体对hTNFalpha（例如，Kd = 10-8M或更低）具有高亲和力，hTNFalpha解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFalpha活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 本发明的抗体或抗体部分可用于检测hTNFα和抑制hTNFα活性，例如在患有hTNFα活性有害的病症的人类受试者中。 用于表达本发明的重组人抗体的核酸，载体和宿主细胞以及合成重组人抗体的方法也包括在本发明中。
-
-
-
-
-
-
-
-
-
Search Results
163
records
(took 0.042 seconds)
